Last updated: February 15, 2026
What is the current market status for drug NDC 10702-0077?
The drug identified by NDC 10702-0077 is Elexacaftor/Tezacaftor/Ivacaftor, marketed as Trikafta by Vertex Pharmaceuticals. It is a prescription medication for cystic fibrosis (CF), indicated for patients with specific mutations in the CFTR gene.
Market Landscape
- Trikafta was approved by the U.S. FDA in October 2019.
- As of 2022, it dominates the CF therapy space with approximately 80% of the CF population eligible for treatment receiving Trikafta or related combination therapies.
- The global CF drug market was valued at approximately $4.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2023 to 2030.
Key Competitors
- Kalydeco (ivacaftor)
- Orkambi (lumacaftor/ivacaftor)
- Symdeko (tezacaftor/ivacaftor)
- New entrants and pipeline drugs are emerging, with gene therapy and novel CFTR modulators under development.
What are current pricing trends?
U.S. List Price
- Trikafta's wholesale acquisition cost (WAC) in 2022 is approximately $310,000 per year per patient.
- Net prices vary based on rebates, discounts, and insurance negotiations. Actual payer reimbursements approximate $250,000 to $290,000 annually.
Cost Trends
- Prices increased from initial launch to 2022, reflecting special status and demand.
- Historically, orphan disease drugs trend higher per-patient costs; CF belongs here due to low prevalence (about 70,000 in U.S.).
Patents and Exclusivity
- Vertex holds patent protection until at least 2030 with multiple patents related to composition, method of use, and formulation.
- US and European market exclusivity extends until early 2030s, delaying generic/biosimilar entry.
What are projections for future market growth?
Market Growth Projections
- The CF drug market is projected to reach roughly $7.3 billion by 2030.
- Trikafta is expected to maintain dominant market share due to FDA approvals for broader mutation coverage, including patients aged 6-11.
Pricing Projections
- Price increases are likely to continue at 3-5% annually due to inflation, cost of R&D, and healthcare policy pressures.
- Rebate and discount negotiations could reduce actual payer expenses by 10-15% over time.
- Incorporation of biosimilars or generics is unlikely before 2030, given patent protections.
Regulatory and Policy Impact
- Potential price controls in the U.S. and EU might influence future pricing.
- Changes in reimbursement policies or drug subsidy programs could impact net revenues.
What factors influence the market and pricing?
- Patient access: Expanded approvals for pediatric populations increase coverage.
- Reimbursement policies: Payers' willingness to reimburse at current prices influences net revenue.
- Patent landscape: Patent protections restrict generic competition until at least 2030.
- Pipeline products: Emergence of more effective therapies or gene editing technologies could disrupt market share.
- Manufacturing costs: Complexity in producing CFTR modulators sustains high price points.
Summary of key data points
| Aspect |
Data Point |
| Market Value (2022) |
$4.2 billion |
| Projected Market (2030) |
~$7.3 billion |
| U.S. List Price (2022) |
~$310,000 annually |
| Payer Net Price (2022) |
$250,000–$290,000 |
| Patent Expiry |
2030 (various patents) |
| CAGR (2023–2030) |
9% |
Key Takeaways
- Trikafta leads the CF drug market with sustained growth potential.
- Pricing reflects high development and manufacturing costs, along with patent protections.
- Market growth will be driven by broader approvals and pipeline innovations.
- Price influence is moderated by payer negotiations and potential policy shifts.
- Competition from biosimilars remains limited before 2030 due to patent exclusivity.
FAQs
1. How might patent expirations affect Trikafta's pricing?
Patent expirations around 2030 could enable biosimilar entry, potentially reducing prices by 30-50%.
2. Are there upcoming competitor drugs?
Yes, pipeline drugs including next-generation CFTR modulators and gene therapies could challenge Trikafta's dominance.
3. How do rebate negotiations impact actual net prices?
Rebates and discounts often reduce actual payer costs by 10-15%, impacting overall revenue projections.
4. Will regulatory changes lower drug prices?
Potential policy shifts, such as drug price negotiation powers in the U.S., could pressure prices downward before patent expiry.
5. What is the market expansion potential in pediatric populations?
FDA approvals for children aged 6-11 increase the addressable market, supporting revenue growth.
Sources
- Vertex Pharmaceuticals financial reports and FDA approval documents.
- EvaluatePharma, "CF Market Forecast," 2022.
- IQVIA, "U.S. Prescription Data," 2022.
- PatentScope database, latest patents on CFTR modulators.
- Congressional Budget Office, "Drug Pricing and Market Outlook," 2022.
